Hydrochlorothiazide / Valsartan Dosage
This dosage information may not include all the information needed to use Hydrochlorothiazide / Valsartan safely and effectively. See additional information for Hydrochlorothiazide / Valsartan.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Hypertension
Hydrochlorothiazide-valsartan is dosed once daily:
Initial dose: 1 tablet (12.5 mg-160 mg) orally once a day.
Maintenance dose: Titrate as necessary (every 1 to 2 weeks) up to a maximum of 25 mg-320 mg orally once a day.
Hydrochlorothiazide-valsartan may be substituted for the titrated components.
Renal Dose Adjustments
CrCl less than 30 mL/min: Hydrochlorothiazide-valsartan is not recommended for this patient with severe renal insufficiency because hydrochlorothiazide is not expected to be filtered into the renal tubule (its site of action) when the glomerular filtration rate is less than 30 mL/min.
Liver Dose Adjustments
Because valsartan is primarily eliminated by the liver, caution is recommended when advancing doses or giving maximum doses to this patient with liver disease. Theoretically, the risk of side effects is higher in this case, especially when higher doses are used.
Hydrochlorothiazide-valsartan is not recommended as initial therapy in patients with intravascular volume depletion.
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Valsartan is not removed by hemodialysis.
The maximum antihypertensive effect is usually seen within 2 to 4 weeks.
Hydrochlorothiazide-valsartan may be administered without regard to meals.
No initial dosage adjustment is required for elderly patients.
A patient whose blood pressure is not adequately controlled with valsartan (or another ARB) alone or hydrochlorothiazide alone may be switched to combination therapy with hydrochlorothiazide-valsartan.
A patient who experiences dose-limiting adverse reactions on either component alone may be switched to hydrochlorothiazide-valsartan containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. The clinical response to hydrochlorothiazide-valsartan should be subsequently evaluated and if blood pressure remains uncontrolled after 3 to 4 weeks of therapy, the dose may be titrated up to a maximum of 320/25 mg.